Structural characterization of antibody-responses from Zolgensma treatment provides the blueprint for the engineering of an AAV capsid suitable for redosing
Mietzsch M., Nelson AR., Hsi J., Zachary J., Potts L., Chipman P., Ghanem M., Khandekar N., Alexander IE., Logan GJ., Huiskonen JT., McKenna R.